Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 24 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 540694 | NSE: ANG

ANG Lifesciences India Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2024, 9:09 pm

Market Cap 60.1 Cr.
Current Price 46.0
High / Low86.1/43.5
Stock P/E
Book Value 56.2
Dividend Yield0.00 %
ROCE1.78 %
ROE8.72 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for ANG Lifesciences India Ltd

Competitors of ANG Lifesciences India Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,399 Cr. 312390/10864.5 20.50.21 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 58.6 Cr. 79.094.9/25.822.5 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 86.2 Cr. 114155/87.012.9 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 12,813 Cr. 1,0461,335/62530.2 2072.15 %28.1 %21.1 % 2.00
Industry Average19,448.38 Cr1,190.0155.11184.880.32%16.40%16.92%6.61

All Competitor Stocks of ANG Lifesciences India Ltd

Quarterly Result

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales118.0087.6847.1295.8771.5658.3945.1731.8850.6129.5817.1034.0816.18
Expenses88.8768.5542.4183.7460.2849.1543.0343.4844.9428.2618.8230.2318.11
Operating Profit29.1319.134.7112.1311.289.242.14-11.605.671.32-1.723.85-1.93
OPM %24.69%21.82%10.00%12.65%15.76%15.82%4.74%-36.39%11.20%4.46%-10.06%11.30%-11.93%
Other Income0.080.110.130.620.120.200.329.200.340.33-0.09-1.491.36
Interest1.341.341.693.513.173.202.841.111.941.961.993.441.67
Depreciation0.361.031.352.371.881.901.922.821.941.972.021.831.51
Profit before tax27.5116.871.806.876.354.34-2.30-6.332.13-2.28-5.82-2.91-3.75
Tax %25.26%24.96%32.78%23.14%47.24%39.63%-30.43%-20.54%25.35%-10.09%-20.96%23.71%-26.13%
Net Profit20.5512.661.225.283.342.62-1.60-5.031.60-2.05-4.59-3.60-2.77
EPS in Rs15.819.740.944.062.572.02-1.23-3.851.23-1.57-3.52-2.76-2.12

Last Updated: October 7, 2024, 8:40 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 3:04 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales16343755677512112615434920713197
Expenses14303450606811011413928319512295
Operating Profit3535671212156612102
OPM %16%14%8%9%10%10%10%10%10%19%6%7%2%
Other Income000001001110-10
Interest222222334811109
Depreciation1311111125987
Profit before tax0012458810532-9-15
Tax %140%56%32%25%26%25%30%28%26%25%132%-2%
Net Profit-00023466740-1-9-13
EPS in Rs-0.070.210.431.793.072.864.354.695.5830.55-0.51-6.62-9.97
Dividend Payout %0%0%0%0%0%0%0%0%0%3%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)50.00%33.33%50.00%0.00%16.67%471.43%-102.50%-800.00%
Change in YoY Net Profit Growth (%)0.00%-16.67%16.67%-50.00%16.67%454.76%-573.93%-697.50%

ANG Lifesciences India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:14%
5 Years:2%
3 Years:-5%
TTM:-37%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-51%
Stock Price CAGR
10 Years:%
5 Years:21%
3 Years:-53%
1 Year:-28%
Return on Equity
10 Years:17%
5 Years:15%
3 Years:14%
Last Year:-9%

Last Updated: Unknown

Balance Sheet

Last Updated: Unknown

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Equity Capital444445555101313
Reserves-1-1-11418242936737264
Borrowings131110121417222142615659
Other Liabilities6111319252830395812411181
Total Liabilities2125263547688194142269252217
Fixed Assets1199999212122827953
CWIP0000012000000
Investments000000000444
Other Assets1016172638476073120183170161
Total Assets2125263547688194142269252217

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +-84323175-112726-13
Cash from Investing Activity +-2-2-2-3-3-13-1-2-8-42-920
Cash from Financing Activity +10-1-12-013-4-41915-17-7
Net Cash Flow00-01-013-1-00-0-0

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-10.00-6.00-7.00-7.00-8.00-10.00-10.00-9.00-27.005.00-44.00-49.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days968062109139156126133139104138192
Inventory Days13784844745532741684693143
Days Payable16912913013316315491106159105154244
Cash Conversion Cycle633416222156626948457792
Working Capital Days594239435079779013373107213
ROCE %20%14%17%26%29%22%24%22%20%54%9%2%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters71.07%71.09%71.14%71.15%71.15%71.15%70.60%70.60%70.60%70.60%70.60%70.60%
Public28.93%28.91%28.86%28.85%28.86%28.85%29.40%29.38%29.41%29.39%29.39%29.39%
No. of Shareholders3232,5224,2595,2156,9396,9467,1637,3057,0556,9186,8686,631

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22
FaceValue10.0010.0010.00
Basic EPS (Rs.)-7.650.3639.39
Diluted EPS (Rs.)-7.650.3639.09
Cash EPS (Rs.)-1.366.9644.56
Book Value[Excl.RevalReserv]/Share (Rs.)58.4166.0280.81
Book Value[Incl.RevalReserv]/Share (Rs.)58.4166.0280.81
Revenue From Operations / Share (Rs.)111.89168.39341.77
PBDIT / Share (Rs.)7.9218.2765.87
PBIT / Share (Rs.)1.5111.1160.20
PBT / Share (Rs.)-8.202.0151.61
Net Profit / Share (Rs.)-7.77-0.2038.89
NP After MI And SOA / Share (Rs.)-7.77-0.2038.89
PBDIT Margin (%)7.0710.8419.27
PBIT Margin (%)1.346.5917.61
PBT Margin (%)-7.331.1915.10
Net Profit Margin (%)-6.94-0.1111.37
NP After MI And SOA Margin (%)-6.94-0.1111.37
Return on Networth / Equity (%)-13.29-0.3048.12
Return on Capital Employeed (%)2.0112.3550.02
Return On Assets (%)-4.18-0.0913.85
Long Term Debt / Equity (X)0.180.230.25
Total Debt / Equity (X)0.900.810.91
Asset Turnover Ratio (%)0.550.770.00
Current Ratio (X)1.241.151.16
Quick Ratio (X)0.900.850.93
Inventory Turnover Ratio (X)2.143.650.00
Dividend Payout Ratio (NP) (%)0.000.002.57
Dividend Payout Ratio (CP) (%)0.000.002.24
Earning Retention Ratio (%)0.000.0097.43
Cash Earning Retention Ratio (%)0.000.0097.76
Interest Coverage Ratio (X)0.942.017.67
Interest Coverage Ratio (Post Tax) (X)0.230.975.53
Enterprise Value (Cr.)122.38163.11313.54
EV / Net Operating Revenue (X)0.830.740.88
EV / EBITDA (X)11.836.844.59
MarketCap / Net Operating Revenue (X)0.400.450.68
Retention Ratios (%)0.000.0097.42
Price / BV (X)0.771.152.90
Price / Net Operating Revenue (X)0.400.450.68
EarningsYield-0.170.000.16

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of ANG Lifesciences India Ltd as of November 24, 2024 is: 74.98

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 24, 2024, ANG Lifesciences India Ltd is Undervalued by 63.00% compared to the current share price 46.00

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of ANG Lifesciences India Ltd as of November 24, 2024 is: 42.77

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 24, 2024, ANG Lifesciences India Ltd is Overvalued by 7.02% compared to the current share price 46.00

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -42.95%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 21.58%, which is a positive sign.
  2. The company has shown consistent growth in sales (113.00 cr) and profit (5.31 cr) over the years.
  1. The stock has a high average Working Capital Days of 83.75, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 50.42, which may not be favorable.
  3. The company has higher borrowings (28.17) compared to reserves (26.50), which may suggest financial risk.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ANG Lifesciences India Ltd:
    1. Net Profit Margin: -6.94%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 2.01% (Industry Average ROCE: 16.4%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -13.29% (Industry Average ROE: 16.92%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 0.23
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.9
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 0 (Industry average Stock P/E: 55.11)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.9
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

No data availabale for About the Company
INDUSTRYADDRESSCONTACT
Industry not foundAddress not foundContact not found
Management Data not Available

FAQ

What is the latest intrinsic value of ANG Lifesciences India Ltd?

The latest intrinsic value of ANG Lifesciences India Ltd as on 24 November 2024 is ₹74.98, which is 63.00% higher than the current market price of ₹46.00.

What is the Market Cap of ANG Lifesciences India Ltd?

The Market Cap of ANG Lifesciences India Ltd is 60.1 Cr..

What is the current Stock Price of ANG Lifesciences India Ltd as on 24 November 2024?

The current stock price of ANG Lifesciences India Ltd as on 24 November 2024 is 46.0.

What is the High / Low of ANG Lifesciences India Ltd stocks in FY 2024?

In FY 2024, the High / Low of ANG Lifesciences India Ltd stocks is 86.1/43.5.

What is the Stock P/E of ANG Lifesciences India Ltd?

The Stock P/E of ANG Lifesciences India Ltd is .

What is the Book Value of ANG Lifesciences India Ltd?

The Book Value of ANG Lifesciences India Ltd is 56.2.

What is the Dividend Yield of ANG Lifesciences India Ltd?

The Dividend Yield of ANG Lifesciences India Ltd is 0.00 %.

What is the ROCE of ANG Lifesciences India Ltd?

The ROCE of ANG Lifesciences India Ltd is 1.78 %.

What is the ROE of ANG Lifesciences India Ltd?

The ROE of ANG Lifesciences India Ltd is 8.72 %.

What is the Face Value of ANG Lifesciences India Ltd?

The Face Value of ANG Lifesciences India Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in ANG Lifesciences India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE